Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Radko Komers

Showing results (11-20 of 66) with videos related to

Pageof 7
Sort By:
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 4, 2008
Glomerular endothelial NOS (eNOS) expression in type 2 diabetic patients with nephropathyRadko Komers, Sharon Anderson
Expert Review of Clinical Immunology|February 16, 2024
Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathyHoward Trachtman, Radko Komers, Jula Inrig
Expert Opinion on Emerging Drugs|July 19, 2023
Status of current trials and potential future trials with sparsentanHoward Trachtman, Radko Komers, Jula Inrig
The New England Journal of Medicine|March 20, 2024
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. ReplyHoward Trachtman, Michelle N Rheault, Radko Komers
British Journal of Pharmacology|May 31, 2016
Effects of xanthine oxidase inhibition with febuxostat on the development of nephropathy in experimental type 2 diabetesRadko Komers, Bei Xu, Jennifer Schneider, et al.
Therapeutic Advances in Rare Disease|July 22, 2025
Sparsentan in IgA nephropathy: a plain language summary of publication for the PROTECT studyBrad H Rovin, Radko Komers, Chris Scroggins, et al.
Lancet (London, England)|November 9, 2024
Sparsentan and kidney protection: improved medullary oxygenation? - Authors' replyDonald Kohan, Jula Inrig, Brad H Rovin, et al.
Kidney International Reports|January 1, 2020
Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial)Jonathan Barratt, Brad Rovin, Ulysses Diva, et al.
Clinical and Experimental Pharmacology & Physiology|January 5, 2007
Cyclo-oxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic ratsRadko Komers, Jessie N Lindsley, Terry T Oyama, et al.
Journal of Nephrology|January 6, 2023
Maximizing the value of the open label extension phase of randomized clinical trialsHoward Trachtman, Rosanna Coppo, Moin Saleem, et al.
Pageof 7

Showing results (11-20 of 66) with videos related to

Sort By:
Pageof 7
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 4, 2008
Glomerular endothelial NOS (eNOS) expression in type 2 diabetic patients with nephropathyRadko Komers, Sharon Anderson
Expert Review of Clinical Immunology|February 16, 2024
Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathyHoward Trachtman, Radko Komers, Jula Inrig
Expert Opinion on Emerging Drugs|July 19, 2023
Status of current trials and potential future trials with sparsentanHoward Trachtman, Radko Komers, Jula Inrig
The New England Journal of Medicine|March 20, 2024
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. ReplyHoward Trachtman, Michelle N Rheault, Radko Komers
British Journal of Pharmacology|May 31, 2016
Effects of xanthine oxidase inhibition with febuxostat on the development of nephropathy in experimental type 2 diabetesRadko Komers, Bei Xu, Jennifer Schneider, et al.
Therapeutic Advances in Rare Disease|July 22, 2025
Sparsentan in IgA nephropathy: a plain language summary of publication for the PROTECT studyBrad H Rovin, Radko Komers, Chris Scroggins, et al.
Lancet (London, England)|November 9, 2024
Sparsentan and kidney protection: improved medullary oxygenation? - Authors' replyDonald Kohan, Jula Inrig, Brad H Rovin, et al.
Kidney International Reports|January 1, 2020
Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial)Jonathan Barratt, Brad Rovin, Ulysses Diva, et al.
Clinical and Experimental Pharmacology & Physiology|January 5, 2007
Cyclo-oxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic ratsRadko Komers, Jessie N Lindsley, Terry T Oyama, et al.
Journal of Nephrology|January 6, 2023
Maximizing the value of the open label extension phase of randomized clinical trialsHoward Trachtman, Rosanna Coppo, Moin Saleem, et al.
Pageof 7